ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 57.86 USD -1.33% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
ANI Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one ANIP stock under the Base Case scenario is 96.33 USD. Compared to the current market price of 57.86 USD, ANI Pharmaceuticals Inc is Undervalued by 40%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ANIP Intrinsic Value
96.33 USD
Undervaluation 40%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ANI Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ANIP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ANIP?
Bearish
Neutral
Bullish

Fundamental Analysis

ANI Pharmaceuticals Inc
US
Pharmaceuticals
Market Cap
1.2B USD
IPO
May 4, 2000
Employees
601
United States of America
Market Cap
1.2B USD
Industry
Pharmaceuticals
IPO
May 4, 2000

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 601 full-time employees. The company went IPO on 2000-05-04. The firm is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The firm focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. The company operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

[ Read More ]

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about ANI Pharmaceuticals Inc

Provide an overview of the primary business activities
of ANI Pharmaceuticals Inc.

What unique competitive advantages
does ANI Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does ANI Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in ANI Pharmaceuticals Inc recently?

Summarize the latest earnings call
of ANI Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ANI Pharmaceuticals Inc.

Provide P/S
for ANI Pharmaceuticals Inc.

Provide P/E
for ANI Pharmaceuticals Inc.

Provide P/OCF
for ANI Pharmaceuticals Inc.

Provide P/FCFE
for ANI Pharmaceuticals Inc.

Provide P/B
for ANI Pharmaceuticals Inc.

Provide EV/S
for ANI Pharmaceuticals Inc.

Provide EV/GP
for ANI Pharmaceuticals Inc.

Provide EV/EBITDA
for ANI Pharmaceuticals Inc.

Provide EV/EBIT
for ANI Pharmaceuticals Inc.

Provide EV/OCF
for ANI Pharmaceuticals Inc.

Provide EV/FCFF
for ANI Pharmaceuticals Inc.

Provide EV/IC
for ANI Pharmaceuticals Inc.

Show me price targets
for ANI Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for ANI Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for ANI Pharmaceuticals Inc?

What are the Net Income projections
for ANI Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for ANI Pharmaceuticals Inc?

What are the EPS projections
for ANI Pharmaceuticals Inc?

How accurate were the past EPS estimates
for ANI Pharmaceuticals Inc?

What are the EBIT projections
for ANI Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for ANI Pharmaceuticals Inc?

Compare the revenue forecasts
for ANI Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ANI Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ANI Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of ANI Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of ANI Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing ANI Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of ANI Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for ANI Pharmaceuticals Inc.

Provide ROE
for ANI Pharmaceuticals Inc.

Provide ROA
for ANI Pharmaceuticals Inc.

Provide ROIC
for ANI Pharmaceuticals Inc.

Provide ROCE
for ANI Pharmaceuticals Inc.

Provide Gross Margin
for ANI Pharmaceuticals Inc.

Provide Operating Margin
for ANI Pharmaceuticals Inc.

Provide Net Margin
for ANI Pharmaceuticals Inc.

Provide FCF Margin
for ANI Pharmaceuticals Inc.

Show all solvency ratios
for ANI Pharmaceuticals Inc.

Provide D/E Ratio
for ANI Pharmaceuticals Inc.

Provide D/A Ratio
for ANI Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for ANI Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for ANI Pharmaceuticals Inc.

Provide Quick Ratio
for ANI Pharmaceuticals Inc.

Provide Current Ratio
for ANI Pharmaceuticals Inc.

Provide Cash Ratio
for ANI Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for ANI Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for ANI Pharmaceuticals Inc?

What is the current Free Cash Flow
of ANI Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for ANI Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ANI Pharmaceuticals Inc

Current Assets 521.3m
Cash & Short-Term Investments 153.3m
Receivables 202.5m
Other Current Assets 165.6m
Non-Current Assets 766.1m
PP&E 56.7m
Intangibles 630.3m
Other Non-Current Assets 79.1m
Current Liabilities 189.9m
Accounts Payable 60.9m
Accrued Liabilities 83.5m
Other Current Liabilities 45.5m
Non-Current Liabilities 666.6m
Long-Term Debt 618.2m
Other Non-Current Liabilities 48.4m
Efficiency

Earnings Waterfall
ANI Pharmaceuticals Inc

Revenue
692.9m USD
Cost of Revenue
-272.5m USD
Gross Profit
420.4m USD
Operating Expenses
-399.1m USD
Operating Income
21.3m USD
Other Expenses
-13.8m USD
Net Income
7.5m USD

Free Cash Flow Analysis
ANI Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ANIP Profitability Score
Profitability Due Diligence

ANI Pharmaceuticals Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROE is Increasing
50/100
Profitability
Score

ANI Pharmaceuticals Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

ANIP Solvency Score
Solvency Due Diligence

ANI Pharmaceuticals Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average D/E
Positive Net Debt
35/100
Solvency
Score

ANI Pharmaceuticals Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ANIP Price Targets Summary
ANI Pharmaceuticals Inc

Wall Street analysts forecast ANIP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANIP is 75.99 USD with a low forecast of 62.62 USD and a high forecast of 88.2 USD.

Lowest
Price Target
62.62 USD
8% Upside
Average
Price Target
75.99 USD
31% Upside
Highest
Price Target
88.2 USD
52% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ANIP?

Click here to dive deeper.

Dividends

ANI Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ANIP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ANIP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ANIP News

See Also

Discover More
What is the Intrinsic Value of one ANIP stock?

The intrinsic value of one ANIP stock under the Base Case scenario is 96.33 USD.

Is ANIP stock undervalued or overvalued?

Compared to the current market price of 57.86 USD, ANI Pharmaceuticals Inc is Undervalued by 40%.

Back to Top